A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Clinical Trial

NCT04088409 Active, Not recruiting

An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Phase 3

Interventional

Disease

Disease type

Paediatric clinical trials

Uveitis

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

16/10/2019

Closing date

17/07/2023

Inclusion criteria :

Exclusion criteria :

Funding

Private

Members involved

Others investigators

Pr Paul Friedemann

Representative

Germany

Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8)

Pr Martin Spitzer

Representative

Germany

Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Dr Johannes Birtel

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Dr Giacomo Maria Bacci

Representative

Italy

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), Pediatric Ophthalmology Rare Diseases (WG3), Retinal Rare Eye Diseases (WG1)

Dr Susana Noval

Representative

Spain

Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader